欢迎访问西安瑞禧生物技术有限公司官方网站

图片名

全国订购热线:
18966759382

首页 > 新闻资讯 > 市场活动

市场活动
行业新闻 市场活动 技术资讯

(±-Darifenacin-d4 hydrobromide,(±-UK-88525-d4 hydrobromide「同位素标记抑制剂」

作者:瑞禧生物 发布时间:2025-06-13 09:12:39 次浏览

生物活性:(±)-Darifenacin-d4 (hydrobromide) is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].
IC50 & Target:mAChR3
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
(±)-Darifenacin-d4 hydrobromide 相关抗体:
Muscarinic Acetylcholine receptor M3 Antibody
Muscarinic Acetylcholine Receptor M2 Antibody (YA2610)
分子量:511.49
Formula:C28H27D4BrN2O2
CAS 号:2747914-16-3
非标记 CAS:133033-93-9
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (530 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418.
 [Content Brief]